First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors
A phase 1/2 trial of DB-1419 in advanced solid tumours, run by DualityBio Inc., now recruiting.
Overview
First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT06554795 by DualityBio Inc., with 360 participants planned, started 2024-09-03 and due to reach its primary completion in 2027-02. Interventions recorded: DB-1419.
Similar pages
not linked directly; found by shared links- TrialA Study of DB-1324 in Advanced/Metastatic Gastrointestinal Tumors
Shares Duality Biotherapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of DB-1310 in Advanced/Metastatic Solid Tumors
Shares Duality Biotherapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialFirst-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors
Shares Duality Biotherapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
Shares Duality Biotherapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
Shares Duality Biotherapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Shares Duality Biotherapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
Shares Duality Biotherapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialDB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Shares Duality Biotherapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.